The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis
Open accessAbstract
Coronavirus disease 2019 (COVID-19), a new form of respiratory and systemic disorder sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now producing an outbreak of pandemic proportions, whereby nearly 110,000 people have already been infected around the world, 10–15% of whom with severe disease and over 3800 already died [1]. A severe form of pneumonia, potentially evolving towards adult respiratory distress syndrome (ARDS) and occasionally associated with multiorgan failure, are the leading complications of this respiratory virus [2]. Since laboratory medicine provides an essential contribution to the clinical decision making in this and many other infectious diseases [3], we aim to investigate here whether procalcitonin, whose values are not substantially modified in patients with viral infections [4], may play a role in distinguishing patients with or without severe COVID-19. We carried out an electronic search in Medline (PubMed interface), Scopus and Web of Science, using the keywords “procalcitonin” AND “2019 novel coronavirus” OR “2019-nCoV” OR “COVID-19” without date (i.e., up to March 3, 2020) and language restrictions. The title, abstract and full text of all documents identified according to these search criteria were scrutinized by the authors, and those reporting data in COVID-19 patients with or without severe disease (defined as needing admission to intensive care unit or use of mechanical ventilation), were finally included in our meta-analysis. The reference list of each article was reviewed (forward and backward citation tracking) for identifying other potentially eligible documents. A meta-analysis was then carried out for calculating the individual and pooled odds ratios (OR) with their relative 95% confidence interval (95% CI), using MetaXL software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). Procalcitonin values were entered as dichotomous variable, i.e., below or above the locally defined reference range (typically ≥ 0.50 ng/mL). Since the heterogeneity (I statistics) did not exceed 50%, a fixed effects model was finally used. Overall, 27 articles could be originally identified using our search criteria, 24 of which were excluded after title, abstract or full text reading, because they did not report procalcitonin values in patients with or without severe COVID-19. An additional document could be identified from the reference list of one of selected articles. Overall, 4 studies were finally included in our meta-analysis [5–8]. The pooled OR of these studies is summarized in Fig. 1, which shows that increased procalcitonin values are associated with a nearly 5-fold higher risk of severe SARS-CoV-2 infection (OR, 4.76; 95% CI, 2.74–8.29). The heterogeneity among the different studies was found to be modest (i.e., 34%) [9]. Although the overall number of COVID-19 patients with increased procalcitonin values seems limited, as highlighted in a recent article [10], the results of this concise meta-analysis of the literature would suggest that serial procalcitonin measurement may play a role for predicting evolution towards a more severe form of disease. There is a plausible explanation for this evidence. The production and release into the circulation of procalcitonin from extrathyroidal sources is enormously amplified during bacterial infections, actively sustained by enhanced concentrations of interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6. Nevertheless, the synthesis of this biomarker is inhibited by interferon (INF)-γ, whose concentration increases during viral infections. It is hence not surprising that the procalcitonin value would remain within the reference range in several patients with noncomplicated SARS-CoV-2 infection, whereby its substantial increase would reflect bacterial coinfection in those developing severe form of disease, thus contributing to complicate the clinical picture, as recently shown in children with viral lower respiratory tract infections [11]. Additional studies are compellingly needed to verify the putative bacterial origin of procalcitonin increase in patients with severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Laboratory abnormalities in patients with COVID-2019 infection
Lippi, G., & Plebani, M. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0198 · Cited by 1,020
Self-citationProcalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future
Schuetz, P., Albrich, W., & Mueller, B. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-107 · Cited by 528
Toward a holistic approach for diagnosing sepsis in the emergency department
Cervellin, G., Schüetz, P., & Lippi, G. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.04.004 · Cited by 20
Self-citation
Cited by
Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
“While only minimal discriminative ability is observed for severity, and lack of data prevented this analysis for mortality, we postulate that elevated PCT may be driven by the 50% secondary infection rate seen in non-survivors versus only 1% survivors [26].”
BackgroundInfluentialSelf-citationLippi, G., Plebani, M., & Henry, B. M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.022 · Cited by 1,706
Self-citationHematological findings and complications of COVID‐19
Terpos, E., Ntanasis‐Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T. N., Politou, M., Psaltopoulou, T., Gerotziafas, G., & Dimopoulos, M. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25829 · Cited by 1,673
Risk factors for severe and critically ill COVID‐19 patients: A review
Gao, Y., Ding, M., Dong, X., Zhang, J., Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y., Fu, W., Li, W., et al. (2021) · Allergy · doi:10.1111/all.14657 · Cited by 1,402
Gandhi, R. T., Lynch, J. B., & del Rio, C. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009249 · Cited by 1,307
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,119
Biomarkers associated with COVID-19 disease progression
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., & Ozben, T. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1770685 · Cited by 890
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter
Pereira, M. R., Mohan, S., Cohen, D. J., Husain, S. A., Dube, G. K., Ratner, L. E., Arcasoy, S., Aversa, M. M., Benvenuto, L. J., Dadhania, D. M., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15941 · Cited by 802
SARS-CoV-2 and Stroke in a New York Healthcare System
Yaghi, S., Ishida, K., Torres, J., Mac Grory, B., Raz, E., Humbert, K., Henninger, N., Trivedi, T., Lillemoe, K., Alam, S., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.030335 · Cited by 740
Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241955 · Cited by 660
Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis
Malik, P., Patel, U., Mehta, D., Patel, N., Kelkar, R., Akrmah, M., Gabrilove, J. L., & Sacks, H. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111536 · Cited by 618
Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620937175 · Cited by 604
SARS-COV-2 infection in children and newborns: a systematic review
Liguoro, I., Pilotto, C., Bonanni, M., Ferrari, M. E., Pusiol, A., Nocerino, A., Vidal, E., & Cogo, P. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-020-03684-7 · Cited by 552
Organ-specific manifestations of COVID-19 infection
Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis-Stathopoulos, I., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00648-x · Cited by 502
COVID-19: from an acute to chronic disease? Potential long-term health consequences
Higgins, V., Sohaei, D., Diamandis, E. P., & Prassas, I. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1860895 · Cited by 405
Stawicki, S., Jeanmonod, R., Miller, A., Paladino, L., Gaieski, D., Yaffee, A., De Wulf, A., Grover, J., Papadimos, T., Bloem, C., et al. (2020) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_86_20 · Cited by 373
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
The microbial coinfection in COVID-19
Chen, X., Liao, B., Cheng, L., Peng, X., Xu, X., Li, Y., Hu, T., Li, J., Zhou, X., & Ren, B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10814-6 · Cited by 330
COVID‐19 and the clinical hematology laboratory
Frater, J. L., Zini, G., d’Onofrio, G., & Rogers, H. J. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13229 · Cited by 311
Grivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T. K., Painter, C. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.024 · Cited by 309
Prediction model and risk scores of ICU admission and mortality in COVID-19
Zhao, Z., Chen, A., Hou, W., Graham, J. M., Li, H., Richman, P. S., Thode, H. C., Singer, A. J., & Duong, T. Q. (2020) · PLOS ONE · doi:10.1371/journal.pone.0236618 · Cited by 301
Haitao, T., Vermunt, J. V., Abeykoon, J., Ghamrawi, R., Gunaratne, M., Jayachandran, M., Narang, K., Parashuram, S., Suvakov, S., & Garovic, V. D. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.024 · Cited by 297
Procalcitonin levels in COVID-19 patients
Hu, R., Han, C., Pei, S., Yin, M., & Chen, X. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106051 · Cited by 296
Biomarkers in COVID-19: An Up-To-Date Review
Samprathi, M., & Jayashree, M. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.607647 · Cited by 290
Zhang, J. J. Y., Lee, K. S., Ang, L. W., Leo, Y. S., & Young, B. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa576 · Cited by 285
Beović, B., Doušak, M., Ferreira-Coimbra, J., Nadrah, K., Rubulotta, F., Belliato, M., Berger-Estilita, J., Ayoade, F., Rello, J., & Erdem, H. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa326 · Cited by 269
Elshazli, R. M., Toraih, E. A., Elgaml, A., El-Mowafy, M., El-Mesery, M., Amin, M. N., Hussein, M. H., Killackey, M. T., Fawzy, M. S., & Kandil, E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238160 · Cited by 253
Zhu, Q.-Q., Gong, T., Huang, G.-Q., Niu, Z.-F., Yue, T., Xu, F.-Y., Chen, C., & Wang, G.-B. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01094-9 · Cited by 20
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE: COVID-19 and Hematology
Kreidieh, F., & Temraz, S. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.078 · Cited by 7
Metadata
- Authors
- Lippi, G., & Plebani, M.
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 505
- Pages
- 190-191
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W3009917784
- Cited by
- 652
- References
- 9
- FWCI
- 17.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.